The announcement builds on AZ's announcement earlier this year that it will invest $2.5 billion in an R&D facility in China, ...

Alpha-1 is a microcosm of the rare disease world. The challenges we face, late diagnoses, inconsistent care, and unaffordable ...

Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...

US Senators Bernie Sanders and Angus King have introduced a bill that seeks to ban direct-to-consumer (DTC) advertising by ...

EVERSANA, a leading provider of global commercial services to the life sciences industry, has announced two strategic ...

A fourth revolution in cancer care is taking shape, one that steps away from the current well-trodden path. This revolution ...

The Health and Human Services (HHS) Secretary named eight hand-picked members of the Advisory Committee on Immunisation ...

Describing the current treatment landscape for primary and secondary bone cancer, Romness explains the potential of their own ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

While Takeda's Qdenga (TAK-003) shot is approved as a two-dose regimen to protect people from the disease in dozens of ...

BioNTech has agreed to buy another specialist in mRNA-based vaccines and therapeutics, fellow German biotech CureVac, in an ...